Carl Icahn yesterday urged Amylin Pharmaceuticals (AMLN), which rejected a $22/share bid from...

|By:, SA News Editor

Carl Icahn yesterday urged Amylin Pharmaceuticals (AMLN), which rejected a $22/share bid from Bristol-Myers (BMY), to pursue a sale process. Icahn, who is Amylin's largest shareholder, reckons the diabetes drugs company could attract more than $22, at which price it would be worth around $3.5B.